World demand for antibiotics remains high due to escalating bacterial resistance and the increased risk of serious infections.
Infectious diseases cause more than 11 million deaths each year. We have many years of experience in this area of medicine, including Merrem , our antibiotic for serious hospital-acquired infections.
Product range
More information about our products is available by clicking on the names below.
| Brand Name | Generic Name |
|---|---|
| Merrem/Meronem | meropenem |
Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 20-Nov-2009 22:46 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
